Last reviewed · How we verify
coadministration of JP-1366 and naproxen
coadministration of JP-1366 and naproxen is a Small molecule drug developed by Onconic Therapeutics Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | coadministration of JP-1366 and naproxen |
|---|---|
| Sponsor | Onconic Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- coadministration of JP-1366 and naproxen CI brief — competitive landscape report
- coadministration of JP-1366 and naproxen updates RSS · CI watch RSS
- Onconic Therapeutics Inc. portfolio CI
Frequently asked questions about coadministration of JP-1366 and naproxen
What is coadministration of JP-1366 and naproxen?
coadministration of JP-1366 and naproxen is a Small molecule drug developed by Onconic Therapeutics Inc..
Who makes coadministration of JP-1366 and naproxen?
coadministration of JP-1366 and naproxen is developed by Onconic Therapeutics Inc. (see full Onconic Therapeutics Inc. pipeline at /company/onconic-therapeutics-inc).
What development phase is coadministration of JP-1366 and naproxen in?
coadministration of JP-1366 and naproxen is in Phase 1.